Skip to content
Company Analysis

Teva Pharmaceutical Industries TEVA

A comprehensive view of key metrics, scores, and financial health for Teva Pharmaceutical Industries

Overview of Teva Pharmaceutical Industries Limited

TEVA NYQ
Healthcare Drug Manufacturers - Specialty & Generic Large Cap
Teva Pharmaceutical Industries Limited (TEVA), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $28.57, about 10.5% undervalued vs fair value, +71.0% 1Y return, placing in the top 25% of its sector.
$28.57
-2.49%
As of March 13, 2026
Previous close • Vol 90d: 43.0%
52-Week Range
Market Cap
$35.70B
Enterprise Value
$49.24B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Teva Pharmaceutical Industries .

Top Beats
No strong beats yet

Quick Facts

Website https://www.tevapharm.com
HQ Tel Aviv-Yafo
Employees 31,173
Fiscal year Dec 31

Next Events

Earnings May 6 Estimated

Fair Value Snapshot

Bear Base Bull
$29
$32
$35
Current: $28.57 +11% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$17.3B
4.3%%
Gross Profit
$8.9B
10.8%%
R&D Expense
$1.0B
1.5%%
Operating Income (EBIT)
$2.1B
858.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
77.1%
Fair

Moderate cash conversion - some working capital drag

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
3/5
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Teva Pharmaceutical Industries 's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
72
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
76
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing TEVA's balance between Growth (31.2%), Profitability (38.1%), and Safety (30.8%). Growth 31% Safety 31% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

61th percentile vs peers
62
Key Signals
EPS Growth YoY 1.84 96p Rev Growth YoY 4.3% 49p Revenue CAGR 3Y 5.0% 48p
Strengths
  • Eps Growth Yoy in top 20% of peers (1.84, 96th percentile)
  • D/E Ratio in top 20% of peers (2.16, 90th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (75%)
Risks

No significant risks identified for this axis.

Profitability

75th percentile vs peers
75
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

60th percentile vs peers
61
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Teva Pharmaceutical Industries .

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$31.57
- - -
+10.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info